This paper presents the global research landscape and scientific progress on occupant thermal comfort in naturally ventilated buildings (OTC-NVB). Despite the growing interest in the area, comprehensive papers on the current status and future developments on the topic are currently lacking. Hence, the publication trends, bibliometric analysis, and systematic literature review of the published documents on OTC-NVB were examined. The search query "Thermal Comfort" AND "Natural Ventilation" AND "Buildings" was designed and executed to recover related documents on the topic from the Elsevier Scopus database. Results showed that 976 documents (comprising articles, conference papers, reviews, etc.) were published on the topic from 1995 to 2021. Further analysis showed that 97.34% of the publications were published in the English language. Richard J.de Dear (University of Sydney, Australia) is the most prolific researcher on OTC-NVB research, while Energy and Buildings has the highest publications. Bibliometric analysis showed high publications, citations, keywords, and co-authorships among researchers, whereas the most occurrent keywords are ventilation, natural ventilation, thermal comfort, buildings, and air conditioning. Systematic literature review demonstrated that OTC-NVB research has progressed significantly from empirical to computer-based studies involving complex mathematical equations, programs, or software like artificial neural networks (ANN) and computational fluid dynamics (CFD). In general, OTC-NVB research findings indicate that physiological, social, and environmental factors considerably influence OTC in NVBs. Future studies will likely employ artificial intelligence or building performance simulation (BPS) tools to examine relationships between OTC and indoor air/environmental quality, human behavior, novel clothing, or building materials in NVBs.
Triple-negative breast cancer is an aggressive cancer with high metastatic potential and limited treatment options. The current study investigated the anticancer activity of the Polybia-derived MP-1 peptide, formulated in poly (lactic-co-glycolic acid) (PLGA) nanoparticles, for inhibiting PD-L1 and epithelial mesenchymal transition (EMT)-associated signalling in triple-negative breast cancer (TNBC). Computational screening of molecules identified MP-1 as a stable high-affinity binder of PD-L1 possessing high anticancer prediction scores. The MP-1-PLGA nanoparticles that were optimized showed the spherical structures with a size of 104.4 nm as well as a PDI of 0.231. Moreover, their encapsulation efficiency was 71.5%. The formulation showed a controlled release with 41.65% over 72 h (p